Top View
- Drugs 2012; 72 (9): 1175-1193 LEADING ARTICLE 0012-6667/12/0009-1175/$55.55/0 Adis ª 2012 Springer International Publishing AG
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- IGF2 and IGF1R in Pediatric Adrenocortical Tumors: Roles in Metastasis and Steroidogenesis
- Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
- MYB Oncoproteins: Emerging Players and Potential Therapeutic Targets in Human Cancer Ylenia Cicirò1 and Arturo Sala 1
- Snapshot: Breast Cancer Kornelia Polyak and Otto Metzger Filho Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215 USA
- Computationally Predicting Clinical Drug Combination Efficacy With
- Crosstalk Between VEGFR and Other Receptor Tyrosine Kinases for TKI Therapy of Metastatic Renal Cell Carcinoma
- Efficacy and Safety of First Line Treatments for Patients with BMJ: First Published As 10.1136/Bmj.L5460 on 7 October 2019
- Combination Therapy Approaches to Target Insulin-Like Growth Factor Receptor Signaling in Breast Cancer
- Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF-1R-MEK5-Erk5 Pathway
- PRODUCT INFORMATION Linsitinib Item No
- GIST Research Updates and Future Directions
- Linsitinib (OSI-906) Versus Placebo for Patients with Locally Advanced Or Metastatic Adrenocortical Carcinoma: a Double-Blind, Randomised, Phase 3 Study
- AHRQ Healthcare Horizon Scanning System – Status Updates
- Decision-Making for Adrenocortical Carcinoma: Surgical
- Biphasic Mathematical Model of Cell–Drug Interaction That Separates
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- Establishing a Preclinical Multidisciplinary Board for Brain Tumors Birgit V
- Medical Approaches in Adrenocortical Carcinoma
- Targeting Resistance Against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib Anne Berberich1,2, Tobias Kessler1,2, Carina M
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Drug Responses Are Conserved Across Patient-Derived Xenograft Models of Melanoma Leading to Identification of Novel Drug Combination Therapies
- Jorge J. Nieva, MD
- Single Technology Appraisal Dacomitinib for Untreated EGFR
- Identification of New Drug Targets in Adrenocortical Carcinoma Through Targeted Mrna Analysis
- Ut Scc 110A Ut Scc 21 Ut Scc 49 Ut Scc 74A
- 2011 Medicines in Development for Women
- IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
- EGFR-Tkis Resistance Via EGFR-Independent Signaling Pathways Qian Liu, Shengnan Yu, Weiheng Zhao, Shuang Qin, Qian Chu* and Kongming Wu*
- Targeting Obesity-Related Dysfunction in Hormonally Driven Cancers
- Endocrinology
- Tyrosine Kinase Inhibitors Enhanced the Efficacy of Conventional Chemotherapeutic Agent in Multidrug Resistant Cancer Cells Shaocong Wu and Liwu Fu*
- Molecular Markers and Targets in Melanoma
- Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis
- LINCS-EPA (May 2015)
- Multi-Parametric Single Cell Evaluation Defines Distinct Drug Responses in Healthy Hematologic Cells That Are Retained in Corresponding Malignant Cell Types
- Multi-Omics Data Integration and Network-Based Analysis Drives a Multiplex Drug Repurposing Approach to a Shortlist of Candidate Drugs Against COVID-19
- SIRT6 Haploinsufficiency Induces BRAFV600E Melanoma Cell
- Evolving Treatment Strategies for Localized and Advanced GIST
- Estrogen Receptor Signaling As a Target for Novel Breast Cancer Therapeutics Jack-Michel Renoir, Véronique Marsaud, Gwendal Lazennec
- A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
- Insulin-Like Growth Factor 1-Induced Enolase 2 Deacetylation by HDAC3 Promotes Metastasis of Pancreatic Cancer
- Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
- PDF File of an Unedited Manuscript That Has Been Accepted for Publication
- Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF-1R- MEK5-Erk5 Pathway
- Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- The Role of Biomarkers in Adrenocortical Carcinoma: a Review of Current Evidence and Future Perspectives
- Curriculum Vitae Christopher Hanyoung Lieu, M.D